Cart 16 Product Products 6 820,04 € (empty)
-
-
-
-
-
-
-
1 x Thyroxine,...299,00 € -
-
-
-
-
-
-
-
-
No products
To be determined Shipping
6 820,04 € Total
Prices are tax excluded
Product successfully added to your shopping cart
Quantity
Total
There are 16 items in your cart. There is 1 item in your cart.
Total products (tax excl.) 6 820,04 €
Total shipping (tax excl.) To be determined
Total (tax excl.) 6 820,04 €
Data sheet of CD44 variant isoform 9 (v9) monoclonal antibody, clone RV3
| Brand | Abnova |
| Product type | Primary antibodies |
| Reactivity | Human |
| Host species | Rat |
| Applications | WB-Ce,IHC-P,IF,Flow Cyt |
More info about CD44 variant isoform 9 (v9) monoclonal antibody, clone RV3
| Brand: | Abnova |
| Reference: | MAB12149 |
| Product name: | CD44 variant isoform 9 (v9) monoclonal antibody, clone RV3 |
| Product description: | Rat monoclonal antibody raised against human CD44 variant isoform 9 (v9). Features of clone RV3: 1. Clone RV3 recognizes CD44 splice isoform 9 (CD44v9), which is upregulated specifically and frequently in various cancer cells. 2. Clone RV3, the only CD44v9 antibody applicable for CSC enrichment in the world, can be used to concentrate cancer stem cells (CSCs) due to high expression of CD44v9 usually found in CSCs. 3. Clone RV3 has been commonly used to detect existence of CD44v9 in cancer cells and CSCs in most influential journals of cancer research. |
| Clone: | RV3 |
| Isotype: | IgG2a |
| Gene id: | 960 |
| Gene name: | CD44 |
| Gene alias: | CDW44|CSPG8|ECMR-III|HCELL|IN|LHR|MC56|MDU2|MDU3|MGC10468|MIC4|MUTCH-I|Pgp1 |
| Gene description: | CD44 molecule (Indian blood group) |
| Immunogen: | Human CD44 variant isoform 8-10 transfected cell. |
| Form: | Liquid |
| Recommend dilutions: | Flow cytomerty (1-10 ug/mL) Cancer stem cell enrichment Immunohistochemistry (0.2 ug/mL) Immunofluorescence (3 ug/mL) Western blot (1 ug/mL) The optimal working dilution should be determined by the end user. |
| Storage buffer: | In PBS |
| Storage instruction: | Store at 2-8°C. Aliquot to avoid repeated freezing and thawing. |
| Quality control testing picture: |  |
| Quality control testing picture note: | Cancer Stem Cells (CSCs) have been identified as a subset of distinct population in many tumors and can drive cancer relapse and metastasis with their abilities to self-renew and differentiate into various types of cancer cells. Development of therapies specifically and effectively targeting CSCs thus is necessary to improve the survival and quality of life for cancer patients, especially for patients with metastatic diseases. Clone RV3 can be used for enrichment of CSCs with a cell sorter, and further be applied for studying mechanisms by which CSCs cause cancer relapse and metastasis to develop new drugs against CSCs with “in vitro sphere forming assayâ€, “in vivo lung metastasis assayâ€, etc. In vitro evaluation of CSCs by “sphere formation assay" In vitro sphere formation assays are colony formation assays used to evaluate the clonogenic potential of CSCs, and can be used to evaluate the potential effects of drugs. The figure above shows the sphere formation ability of CD44v9-High and CD44v9-Low cell populations sorted from a human prostate cancer cell line (PC-3) by using anti-CD44v9 monoclonal antibody, clone RV3 (Cat # MAB12149). The increased number of spheres observed in CD44v9-High population (CSC enriched) allows further accurate assessment for the effects of inhibitory drugs and other treatments on CSC sphere formation. In vivo evaluation of CSCs by "lung metastasis assay" Lung metastasis assay, injecting tumorigenic cells into mice intravenously, provides an opportunity to assess the inhibitory effects of compounds or other treatments on the ability of CSC to colonize. Injection of sorted CD44v9-High cells significantly increased the efficiency of metastasis formation and would be applied to evaluate the effectiveness of new anti-CSC therapeutic strategies. |
| Note: | Cancer Stem Cell Enrichment |
| Product type: | Primary antibodies |
| Host species: | Rat |
| Antigen species / target species: | Human |
| Reactivity: | Human |
| Application image: |  |
| Application image note: | CSC enrichment from human cancer cell lines using anti-CD44v9 monoclonal antibody, clone RV3 (Cat # MAB12149) at 3 ug/mL. |
| Applications: | WB-Ce,IHC-P,IF,Flow Cyt |
| Shipping condition: | Blue Ice |